Skip to content

Clinical evaluation of traditional Chinese medicine fire moxibustion in the treatment of chronic nonspecific low back pain: a single-center randomized, parallel and controlled study

Clinical efficacy evaluation of traditional Chinese medicine fire moxibustion in treating chronic non-specific low back pain

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2022000108
Enrollment
Unknown
Registered
2022-10-29
Start date
2022-11-11
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic nonspecific low back pain

Interventions

Control group:Diclofenac sodium sustained-release tablets
Treatment group:Chinese medicine fire moxibustion treatment

Sponsors

Guang'anmen Hospital of Chinese Academy of traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of non-specific low back pain in western medicine; 2. TCM syndrome differentiation is cold-dampness lumbago syndrome; 3. There is no limit to gender, and the age is over 18 years old and under 60 years old; 4. VAS scores ranged from 3 to 7; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who have a history of lumbar surgery; 2. Those with exact etiology or clear pathological changes caused by spinal deformity, infection, tumor, rheumatoid or urinary system diseases; 3. Patients with severe cardiovascular and cerebrovascular diseases or liver and kidney diseases; 4. Patients who have suffered from acute myocardial infarction, cerebrovascular accident, severe trauma, PCI and other patients who need to take non-steroidal drugs for a long time within half a year; 5. Allergic constitution or those who may be allergic to this treatment; 6. Persons with mental illness, alcohol or drug dependence; 7. Those with malignant tumor or related medical history; 8. Pregnant, lactating women or those who plan to become pregnant during the trial or whose spouse plans to become pregnant; 9. Those who have infectious skin diseases or skin injuries; 10. Subjects participated in other clinical trials within one month.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;Serum 5-hydroxytryptamine;Serum beta-endorphin;TCM syndrome curative effect score;

Secondary

MeasureTime frame
Comfort evaluation;Oswestry Disability Index;Satisfaction;Quality of life score SF-36;

Countries

China

Contacts

Public Contactchen xingjuan
chxjuan1985@163.com13699298225

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026